Molli
- Company typePrivate
- Founded2018
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Molli firmographics
Firmographics- Name
- Molli
- Legal name
- Molli Surgical Inc.
- Website
- https://mollisurgical.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Molli industry classification
Industry- Product category
- Medical Devices - Surgical Localization
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)
Keywords
Where Molli is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Markets served
Molli business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Marketing or Sales, Operations, Personnel
Distribution channels1 record
Marketing channels2 records
Molli product offering
Product offeringCore offering
Molli Surgical develops and manufactures a wire-free soft tissue localization device used to mark and ease the removal of lesions during breast-conserving surgery (lumpectomy). The system eliminates the need for traditional radioactive seeds or guide wires, enabling precise tumor localization for breast surgeons and their patients. Following Stryker's July 2024 acquisition, the product is distributed as part of Stryker's breast surgery portfolio.
Product overview
Molli Surgical, now part of Stryker, offers a wire-free soft tissue localization system for breast-conserving surgery. The technology was integrated into Stryker's breast surgery portfolio following the July 2024 acquisition, joining existing offerings such as the SPY-PHI Fluorescence Imaging System for perfusion assessment and lymphatic mapping, SPY AGENT GREEN imaging agent, and DermACELL acellular dermal matrix from LifeNet Health. Molli's localization technology complements Stryker's comprehensive breast care solutions spanning from diagnosis through surgical intervention.
Differentiator
Problem solved
Functional benefit
Products and services
- Molli Surgical Soft Tissue Localization System Wire-free soft tissue localization system designed for breast-conserving surgery (lumpectomy), enabling precise tumor localization without traditional guide wires or radioactive seeds. Targeted at breast surgeons, surgical oncologists, and hospital breast surgery programs.
Companies that use Molli
Customer profileSegments1 record
Ideal customer profiles1 record
Molli technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Molli partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- LifeNet HealthcoreLifeNet Health is Stryker's trusted partner for tissue processing, providing DermACELL acellular dermal matrix products used in breast reconstruction procedures. LifeNet Health has over 40 years of experience in tissue processing and holds the longest-running accreditation with the American Association of Tissue Banks (AATB).
Recent moves3 records
Expansion highlights4 records
Molli competitors and assessment
Company assessmentDirect peers
- Sirius Medical: Sirius Medical's Pintuition system is a wire-free, non-radioactive soft tissue localization platform for breast-conserving surgery. It is the closest direct competitor to Molli on technology approach and clinical use case.
- Hologic (Endomag Magseed): Magseed is a magnetic marker used for wire-free breast lesion localization. Through its Endomag acquisition, Hologic offers a directly comparable technology to Molli for guiding breast-conserving surgery.
- Merit Medical (Cianna Medical SCOUT): SCOUT is a radar-based, wire-free breast lesion localization system acquired by Merit Medical. It directly competes with Molli by offering an alternative non-radioactive, non-wire localization workflow in breast-conserving surgery.
Broad incumbents
- Leica Biosystems (Danaher): Leica Biosystems is a leading provider of breast cancer diagnostics and surgical pathology tools used downstream of lumpectomy procedures. Comparable as part of the broader breast cancer surgical care continuum where Molli is used.
- Devicor Medical (Mammotome, under Danaher): Mammotome provides breast biopsy markers and localization wires used during lumpectomy. It represents the legacy standard-of-care workflow (wire/seed localization) that Molli's wire-free technology is positioned to displace.
- Stryker: Stryker is Molli's parent company and the broader incumbent in the breast surgery ecosystem, including SPY-PHI fluorescence imaging and DermACELL acellular dermal matrix. Comparable as the platform into which Molli's localization technology is now integrated.
- BD (Becton Dickinson): BD offers a portfolio of breast surgery and biopsy tools, including localization devices and the EnCor breast biopsy system. It is a broad incumbent operating in the same surgical specialty as Molli.
- Danaher (Mammotome): Mammotome, a Danaher operating company, provides vacuum-assisted breast biopsy and surgical markers used during breast-conserving surgery. It competes broadly with Molli's breast surgery workflow.
Others
- iCAD: iCAD provides AI-powered breast cancer detection and risk assessment tools used upstream of breast-conserving surgery. Comparable as an enabling technology in the breast cancer care pathway where Molli's localization device is deployed.
Emerging players
- IceCure Medical: IceCure develops cryoablation systems for breast tumors, including for early-stage breast cancer as a non-surgical alternative. It overlaps with Molli in the breast tumor treatment decision pathway but addresses a different patient segment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Molli social profiles
Digital presenceMolli financial estimates
Financial estimateRevenue estimate
Valuation estimate
Molli leadership team
Management profileNumber of profiles
Profiles3 records
Molli funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Molli M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Molli
What does Molli do?
Molli Surgical develops and manufactures a wire-free soft tissue localization device used to mark and ease the removal of lesions during breast-conserving surgery (lumpectomy). The system eliminates the need for traditional radioactive seeds or guide wires, enabling precise tumor localization for breast surgeons and their patients. Following Stryker's July 2024 acquisition, the product is distributed as part of Stryker's breast surgery portfolio.
Is Molli a public or private company?
Molli is a private company. It is classified as corporate owned and is currently acquired.
When was Molli founded?
Molli was founded in 2018. It employs 11 to 50 people.
Where is Molli based?
Molli is headquartered in Toronto, Canada, in the North America region.
Who are Molli's main competitors?
Direct peers on record are Sirius Medical, Hologic (Endomag Magseed) and Merit Medical (Cianna Medical SCOUT). Broad incumbents are Leica Biosystems (Danaher), Devicor Medical (Mammotome, under Danaher), Stryker, BD (Becton Dickinson) and Danaher (Mammotome). iCAD is listed as an others. IceCure Medical is listed as an emerging player.
Does Molli have an API?
No public API is recorded for Molli.
What industry is Molli in?
Molli's product category is Medical Devices - Surgical Localization. Its primary akta.pro industry code is HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339112 and its SIC code is 3841.